enlightenbio

3.9K posts

enlightenbio banner
enlightenbio

enlightenbio

@enlightenbio

healthcare insight seekers #genetics #genomics #precisionmedicine Sign up for our newsletter https://t.co/QNwiNCdB3X

Palo Alto, CA Katılım Mayıs 2013
776 Takip Edilen1.2K Takipçiler
enlightenbio retweetledi
NOTRELOAD AI
NOTRELOAD AI@notreload_ai·
“Up to 40% of the weight patients lose on GLP-1 drugs [ $LLY, $NVO ] may actually be due to decreases in lean muscle mass,” $REGN CSO George Yancopoulos said in an interview at the annual JPMorgan Healthcare Conference. This could “potentially be a public health disaster.”
English
1
1
0
302
enlightenbio retweetledi
Kyle LaHucik
Kyle LaHucik@ky_lahucik·
Three acquisitions to start the first day of #JPM24 J&J’s first full-on bio acquisition in a while + addition to ADC flurry: $2B for Ambrx Merck’s $680M for Harpoon’s T cell engagers & Novartis’ $250M upfront for autoimmune work at Calypso @endpts endpts.com/jj-makes-2b-pu…
English
0
9
36
9.6K
enlightenbio retweetledi
Pearl Freier
Pearl Freier@PearlF·
Amgen SVP Business Development Rachna Khosla said 50% of their revenues today came from business development activities. Much of their pipeline is influenced by BD even though they have a robust research engine she said. #JPM24. Racha said they ask themselves where is the best innovation coming from & how Amgen will add value as a partner
Pearl Freier@PearlF

On @endpts dealmaking panel #jpm24, Roche’s Global Head of Partnering James Sabry expects potential early stage partners to articulate the potential of that medicine as exquisitely as they can with the little amount of data they have

English
0
5
30
8.3K
enlightenbio retweetledi
Velsera
Velsera@velseraofficial·
enlightenbio recently published an interview with Velsera CEO Gavin Nichols. In this wide-ranging discussion, our CEO explained how Velsera will be evolving and growing to improve the precision of R&D, democratize omics and bring clinical decision making to the bedside.
enlightenbio@enlightenbio

Latest interview w/G.Nichols (CEO @ Velsera @velseraofficial discussing their company vision after their formation w/@UgenTec, @SevenBridges, & @pieriandx GN: “Ultimately, we have more of a platform mindset.. the product mindset creates artificial silos.” enlightenbio.com/news-and-featu…

English
0
1
4
151
enlightenbio retweetledi
Element Biosciences
Element Biosciences@ElemBio·
Seamless integration of Element’s sequencing technology with @BioRadGenomics SEQuoia portfolio helps enable cost-effective, flexible, & high-quality sequencing data for our customers. Learn more in Bio-Rad’s presentation tomorrow at #AGBT23. Read the news: prn.to/3JOkw4l
Element Biosciences tweet media
English
0
1
4
459
AGBT Meeting
AGBT Meeting@agbt·
AGBT INSIDE LOOK! @ATJCagan turns taking notes at the 2023 @AGBT General Meeting into an art form. Here's a behind the scenes look how he did the sketch work for the @genetisaur talk this morning. Enjoy! #AGBT23
English
1
6
53
7.8K
enlightenbio retweetledi
Abizar Lakdawalla
Abizar Lakdawalla@LAbizar·
#AGBT23 @nanostringtech lunch session, 1470 installed base across nCounter, GeoMx(20k RNA, 100s proteins, 60 samples/wk, + NGS), CosMx (sub cell. res., 1k plex, 2-20 slides/wk, 300mm2 imaging area). 700 employees.
English
0
1
2
287
enlightenbio retweetledi
Chris Mason
Chris Mason@mason_lab·
Hanlee Ji showing how to call mutations from single cell cDNA libraries with @nanopore adaptive sampling and getting 99% overlap! #AGBT23
Chris Mason tweet mediaChris Mason tweet mediaChris Mason tweet media
English
0
11
69
7.3K
enlightenbio retweetledi
Ruby Gadelrab
Ruby Gadelrab@DivaBiotech·
The key thing i have learned from #SCOPE2023 so far is that KOL programs are dying rapidly. The digital health world doesn’t want to follow the old rules that were made for pharma. KOL program are flawed and creating health disparities
Florida, USA 🇺🇸 English
1
1
8
1.4K

Keşfet

@IsomorphicLabs @EliLillyandCo @Novartis @endpts @BiomeMed @Mendelspod @ElegenBio @velseraofficial